Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle.
Alzheimer disease (AD) is the most common form of dementia in the elderly and the number of individuals developing the disease is rapidly rising. Interventions focused on reducing beta-amyloid (Abeta), a component of senile plaques within the AD brain offer a promising approach to prevent or slow disease progression. In this review, we describe the immune system and cognitive and neurobiological features of a natural model of human brain aging, the beagle. The immune system of dogs shares many features of the human immune system, including developmental and aging characteristics. Further, dogs naturally accumulate human sequence Abeta as they age, which coincides with declines in learning and memory. A longitudinal study (approximately 2 years) of the response of aged beagles to vaccination with fibrillar Abeta1-42 indicated that despite significant clearance of Abeta, there were limited benefits in cognitive function. However, there was evidence for maintenance of executive function over time. These results are strikingly similar to reports of human clinical immunotherapy trials. We propose that the canine model complements existing animal models and will be helpful in developing new vaccine approaches to slowing or preventing Abeta pathology that can be translated to human clinical trials.
Vasilevko
Vitaly
V
Institute for Brain Aging & Dementia, University of California, Irvine, CA 92697-4540, USA.
Head
Elizabeth
E
D000375:Aging / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D004285:Dogs; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000639:trends; D016233:Immunotherapy, Active / Q000379:methods* / Q000639:trends; D058225:Plaque, Amyloid / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D013045:Species Specificity; D016896:Treatment Outcome; D014612:Vaccines / Q000302:isolation & purification / Q000494:pharmacology
D016229:Amyloid beta-Peptides; D014612:Vaccines